Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06188676
Status:
RECRUITING
Last Update Posted:
2024-01-03
First Post:
2023-03-06
Brief Title:
Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg Nivo40 in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
Sponsor:
National Research Center for Hematology Russia
Organization:
National Research Center for Hematology Russia
Study Overview
Official Title:
Nivolumab at the Fixed Dose 40 mg Nivo40 in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This compares the effects of nivolumab at a fixed dose of 40 mg with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma PMBCL Immunotherapy with monoclonal antibodies such as nivolumab may help the bodys immune system attack the cancer and may interfere with the ability of cancer cells to grow and spread Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab Chemotherapy drugs work in different ways to stop the growth of cancer cells either by killing the cells by stopping them from dividing or by stopping them from spreading Rituximab is a monoclonal antibody It binds to a protein called CD20 which is found on B cells a type of white blood cell and some types of cancer cells This may help the immune system kill cancer cells Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None